A Multi-Target Phytotherapeutic Approach to Benign Prostatic Hyperplasia: Preclinical Characterization of a PhytoBPH-Mix

<b>Background:</b> Benign prostatic hyperplasia (BPH) is a prevalent condition affecting over 50% of men aged 60 and above, often leading to lower urinary tract symptoms that significantly impact quality of life. Current pharmacological treatments, including α-adrenergic receptor antagonists and 5α-reductase inhibitors, are associated with adverse effects, prompting the exploration of alternative therapies. This study investigates the potential role of a novel multi-component phytocomplex (PhytoBPH-Mix) comprising <i>Serenoa repens</i>, <i>Pygeum africanum</i>, <i>Urtica dioica</i>, <i>Epilobium angustifolium</i> L., <i>Protium heptaphyllum</i>, lycopene, Vitamin E, zinc, and selenium. <b>Methods</b>: The anti-androgenic, anti-inflammatory, and antimicrobial properties of the mixture were evaluated in vitro. <b>Results:</b> The formulation significantly inhibited 5α-reductase activity, reduced the release of pro-inflammatory cytokines (IL-6 and TNF-α), and exhibited antibacterial effects against <i>E. coli</i> compared to individual extracts. <b>Conclusions</b>: These findings suggest that this specific mixture offers a promising natural alternative or an adjuvant for managing BPH by targeting multiple pathological mechanisms with minimal side effects and could also serve as an effective adjuvant in conventional therapy.